Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.12
EBS's Cash to Debt is ranked higher than
58% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. EBS: 1.12 )
EBS' s 10-Year Cash to Debt Range
Min: 0.53   Max: No Debt
Current: 1.12

Equity to Asset 0.59
EBS's Equity to Asset is ranked higher than
69% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. EBS: 0.59 )
EBS' s 10-Year Equity to Asset Range
Min: -1.27   Max: 0.78
Current: 0.59

-1.27
0.78
Interest Coverage 7.05
EBS's Interest Coverage is ranked higher than
51% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 7.05 )
EBS' s 10-Year Interest Coverage Range
Min: 7.05   Max: 9999.99
Current: 7.05

7.05
9999.99
F-Score: 5
Z-Score: 3.20
M-Score: -2.93
WACC vs ROIC
7.46%
7.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.90
EBS's Operating margin (%) is ranked higher than
90% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. EBS: 12.90 )
EBS' s 10-Year Operating margin (%) Range
Min: -0.8   Max: 48.09
Current: 12.9

-0.8
48.09
Net-margin (%) 8.16
EBS's Net-margin (%) is ranked higher than
88% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. EBS: 8.16 )
EBS' s 10-Year Net-margin (%) Range
Min: -1.22   Max: 46.34
Current: 8.16

-1.22
46.34
ROE (%) 7.29
EBS's ROE (%) is ranked higher than
91% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. EBS: 7.29 )
EBS' s 10-Year ROE (%) Range
Min: 5.5   Max: 214.39
Current: 7.29

5.5
214.39
ROA (%) 4.48
EBS's ROA (%) is ranked higher than
91% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. EBS: 4.48 )
EBS' s 10-Year ROA (%) Range
Min: 4.23   Max: 150.96
Current: 4.48

4.23
150.96
ROC (Joel Greenblatt) (%) 15.78
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. EBS: 15.78 )
EBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.74   Max: 115.65
Current: 15.78

10.74
115.65
Revenue Growth (3Y)(%) 9.20
EBS's Revenue Growth (3Y)(%) is ranked higher than
83% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. EBS: 9.20 )
EBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.1   Max: 31.4
Current: 9.2

-1.1
31.4
EBITDA Growth (3Y)(%) 21.60
EBS's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. EBS: 21.60 )
EBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 21.6
Current: 21.6

0
21.6
EPS Growth (3Y)(%) 7.70
EBS's EPS Growth (3Y)(%) is ranked higher than
84% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. EBS: 7.70 )
EBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.7   Max: 61.7
Current: 7.7

-26.7
61.7
» EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

EBS Guru Trades in Q1 2014

Joel Greenblatt 258,760 sh (New)
John Burbank 7,987 sh (New)
Paul Tudor Jones 20,743 sh (New)
Jim Simons 762,898 sh (+35.36%)
John Rogers Sold Out
Ken Fisher 398,670 sh (-0.23%)
Steven Cohen 401,847 sh (-56.03%)
» More
Q2 2014

EBS Guru Trades in Q2 2014

Paul Tudor Jones 29,400 sh (+41.73%)
Ken Fisher 468,757 sh (+17.58%)
John Burbank Sold Out
Joel Greenblatt 221,928 sh (-14.23%)
Jim Simons 607,511 sh (-20.37%)
» More
Q3 2014

EBS Guru Trades in Q3 2014

Ken Fisher 483,328 sh (+3.11%)
Joel Greenblatt Sold Out
Jim Simons 539,411 sh (-11.21%)
Paul Tudor Jones 24,000 sh (-18.37%)
» More
Q4 2014

EBS Guru Trades in Q4 2014

Ken Fisher 501,428 sh (+3.74%)
Jim Simons 511,111 sh (-5.25%)
Paul Tudor Jones 7,500 sh (-68.75%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 57.10
EBS's P/E(ttm) is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 57.10 )
EBS' s 10-Year P/E(ttm) Range
Min: 6.72   Max: 71.97
Current: 57.1

6.72
71.97
Forward P/E 23.53
EBS's Forward P/E is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 23.53 )
N/A
PE(NRI) 59.40
EBS's PE(NRI) is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 59.40 )
EBS' s 10-Year PE(NRI) Range
Min: 6.69   Max: 71.14
Current: 59.4

6.69
71.14
P/B 2.00
EBS's P/B is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. EBS: 2.00 )
EBS' s 10-Year P/B Range
Min: 0.84   Max: 3.82
Current: 2

0.84
3.82
P/S 2.90
EBS's P/S is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. EBS: 2.90 )
EBS' s 10-Year P/S Range
Min: 0.81   Max: 4.34
Current: 2.9

0.81
4.34
PFCF 21.80
EBS's PFCF is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 21.80 )
EBS' s 10-Year PFCF Range
Min: 5.52   Max: 748.33
Current: 21.8

5.52
748.33
POCF 14.70
EBS's POCF is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 14.70 )
EBS' s 10-Year POCF Range
Min: 2.96   Max: 106.04
Current: 14.7

2.96
106.04
EV-to-EBIT 18.12
EBS's EV-to-EBIT is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 18.12 )
EBS' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 43.5
Current: 18.12

3.3
43.5
PEG 34.94
EBS's PEG is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 34.94 )
EBS' s 10-Year PEG Range
Min: 8.43   Max: 66.15
Current: 34.94

8.43
66.15
Shiller P/E 32.50
EBS's Shiller P/E is ranked higher than
98% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 32.50 )
EBS' s 10-Year Shiller P/E Range
Min: 13.29   Max: 34.71
Current: 32.5

13.29
34.71
Current Ratio 4.65
EBS's Current Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. EBS: 4.65 )
EBS' s 10-Year Current Ratio Range
Min: 1.22   Max: 4.82
Current: 4.65

1.22
4.82
Quick Ratio 3.94
EBS's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. EBS: 3.94 )
EBS' s 10-Year Quick Ratio Range
Min: 0.83   Max: 4.56
Current: 3.94

0.83
4.56
Days Inventory 172.71
EBS's Days Inventory is ranked higher than
83% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 172.71 )
EBS' s 10-Year Days Inventory Range
Min: 80.35   Max: 311.38
Current: 172.71

80.35
311.38
Days Sales Outstanding 32.39
EBS's Days Sales Outstanding is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. EBS: 32.39 )
EBS' s 10-Year Days Sales Outstanding Range
Min: 7.07   Max: 124.36
Current: 32.39

7.07
124.36

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.90
EBS's Price/Tangible Book is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. EBS: 2.90 )
EBS' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 3.92
Current: 2.9

0.88
3.92
Price/DCF (Projected) 2.90
EBS's Price/DCF (Projected) is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 2.90 )
EBS' s 10-Year Price/DCF (Projected) Range
Min: 1.54   Max: 2.12
Current: 2.9

1.54
2.12
Price/Median PS Value 1.40
EBS's Price/Median PS Value is ranked higher than
81% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. EBS: 1.40 )
EBS' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.04
Current: 1.4

0.39
2.04
Price/Peter Lynch Fair Value 9.40
EBS's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 9.40 )
EBS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.55   Max: 0.6
Current: 9.4

0.55
0.6
Price/Graham Number 2.40
EBS's Price/Graham Number is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 2.40 )
EBS' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 2.61
Current: 2.4

0.51
2.61
Earnings Yield (Greenblatt) 5.50
EBS's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. EBS: 5.50 )
EBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 30.2
Current: 5.5

2.3
30.2
Forward Rate of Return (Yacktman) 8.87
EBS's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.81 vs. EBS: 8.87 )
EBS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.3   Max: 9.1
Current: 8.87

-12.3
9.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc., was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company's products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 

More From Other Websites
MedImmune, Tech Council of Maryland chart path for region's biotech community Mar 30 2015
26.03.2015 - Austrian’s rich are getting richer: Assets high of 138 billion Euros Mar 30 2015
FDA approves Emergent BioSolutions' inhaled anthrax treatment Mar 25 2015
FDA approves Emergent BioSolutions' anthrax treatment Mar 25 2015
Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in... Mar 25 2015
Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in... Mar 25 2015
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next... Mar 24 2015
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next... Mar 24 2015
U.S. funding research of better anthrax vaccine -health officials Mar 23 2015
Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog Mar 17 2015
Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the... Mar 16 2015
Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the... Mar 16 2015
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2015
EMERGENT BIOSOLUTIONS INC. Financials Mar 13 2015
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides... Mar 12 2015
Emergent BioSolutions, MorphoSys Start Cancer Drug Study - Analyst Blog Mar 10 2015
Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK